NO20081550L - Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske - Google Patents

Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske

Info

Publication number
NO20081550L
NO20081550L NO20081550A NO20081550A NO20081550L NO 20081550 L NO20081550 L NO 20081550L NO 20081550 A NO20081550 A NO 20081550A NO 20081550 A NO20081550 A NO 20081550A NO 20081550 L NO20081550 L NO 20081550L
Authority
NO
Norway
Prior art keywords
reduction
tears
preventive
therapeutic agent
present
Prior art date
Application number
NO20081550A
Other languages
English (en)
Inventor
Mamoru Kobayashi
Tetsuya Asari
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of NO20081550L publication Critical patent/NO20081550L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer farmasøytiske midler for hindring eller behandling av sykdommer assosiert med tårereduksjon. Dvs. foreliggende oppfinnelse tilveiebringer farmasøytiske midler for hindring eller behandling av sykdommer assosiert med reduksjon av tårer slik som tørt øye, tørre forstyrrelser vedrørende hornhinne og conjunctiva, forstyrrelser vedrørende keratoconjunctival epitelium, syndrom med reduksjon i tåresekresjon, xeroftalmi, tørt øye på grunn av aldring, oftalmomopati ved Stevens-Johnson syndrom, oftalmopati ved Sjögrens syndrom, keratoconjunctival ulcer, tørrhet ved bruk av kontaktlinser eller lignende, som innebefatter en ?3-adrenoseptorstimulant. Foreliggende oppfinnelse tilveiebringer også et kombinasjonsfarmasøytisk middel som innebefatter en ?3-adrenoseptorstimulant og en ?2-adrenoseptorstimulant.
NO20081550A 2005-08-29 2008-03-31 Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske NO20081550L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005247563 2005-08-29
PCT/JP2006/316836 WO2007026630A1 (ja) 2005-08-29 2006-08-28 涙液の減少に伴う疾患の予防又は治療剤

Publications (1)

Publication Number Publication Date
NO20081550L true NO20081550L (no) 2008-05-28

Family

ID=37808722

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081550A NO20081550L (no) 2005-08-29 2008-03-31 Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske

Country Status (14)

Country Link
US (1) US20100197788A9 (no)
EP (1) EP1938837A4 (no)
JP (1) JPWO2007026630A1 (no)
KR (1) KR20080038412A (no)
CN (1) CN101252952A (no)
AU (1) AU2006285963A1 (no)
BR (1) BRPI0615339A2 (no)
CA (1) CA2619445A1 (no)
IL (1) IL189620A0 (no)
NO (1) NO20081550L (no)
RU (1) RU2008112176A (no)
TW (1) TW200744635A (no)
WO (1) WO2007026630A1 (no)
ZA (1) ZA200801858B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007061114A1 (ja) * 2005-11-28 2007-05-31 Kissei Pharmaceutical Co., Ltd. 神経因性疼痛の予防又は治療用医薬組成物
WO2007114315A1 (ja) * 2006-03-30 2007-10-11 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
EP2123268A1 (en) * 2007-02-21 2009-11-25 Kissei Pharmaceutical Co., Ltd. Pharmaceutical composition for prevention or treatment of disease associated with tear reduction
JPWO2010041568A1 (ja) 2008-10-09 2012-03-08 旭化成ファーマ株式会社 インダゾール誘導体
AU2009301798B2 (en) 2008-10-09 2012-03-01 Asahi Kasei Pharma Corporation Indazole compound
US20100222404A1 (en) * 2008-11-04 2010-09-02 Asahi Kasei Pharma Corporation Indazole derivative dihydrochloride
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
EP2506843A4 (en) * 2009-12-02 2013-04-17 Bridge Pharma Inc TREATMENT OF THE DRY EYE WITH COMPOUNDS TO INCREASE MOMENTUM DRY SECRETION
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
GB201612165D0 (en) * 2016-07-13 2016-08-24 Atrogi Ab Combinations for the treatment of type 2 diabetes
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5768684A (en) * 1994-03-04 1998-06-16 Motorola, Inc. Method and apparatus for bi-directional power control in a digital communication system
KR980007105A (ko) * 1996-06-28 1998-03-30 김광호 이동국 송신전력 제어방법
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
US6064659A (en) * 1998-07-10 2000-05-16 Motorola, Inc. Method and system for allocating transmit power to subscriber units in a wireless communications system
JP3471662B2 (ja) * 1998-08-28 2003-12-02 松下電器産業株式会社 送受信装置及びその送信電力制御方法
US6311070B1 (en) * 1999-03-22 2001-10-30 Nortel Networks Limited Variable step size for power control bits to protect against power overshoot
EP1045529B1 (en) * 1999-04-12 2006-11-29 Alcatel A method for improving performances of a mobile radiocommunication system using a power control algorithm
WO2001041806A1 (fr) 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Compositions ophtalmiques
KR100324425B1 (ko) * 1999-12-29 2002-02-27 박종섭 Ｃｄｍａ 시스템에서의 기지국 및 이동국간 순방향/역방향링크 전력제어 방법
JP2001268637A (ja) * 2000-03-15 2001-09-28 Nec Corp 移動機及び基地局並びにそれ等を用いた移動通信システム
CA2313290A1 (en) * 2000-06-30 2001-12-30 Frank Van Heeswyk Adaptive rate power control cdma system
US6856644B1 (en) * 2000-10-31 2005-02-15 Motorola, Inc. Method and apparatus for forward link power control bit generation in a spread-spectrum communication system
JP3577021B2 (ja) * 2001-09-12 2004-10-13 埼玉日本電気株式会社 移動局および移動局における電界状態判定方法
AU2004212381B2 (en) 2003-02-14 2008-08-21 Kissei Pharmaceutical Co., Ltd. Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof

Also Published As

Publication number Publication date
ZA200801858B (en) 2009-07-29
US20080306160A1 (en) 2008-12-11
WO2007026630A1 (ja) 2007-03-08
JPWO2007026630A1 (ja) 2009-03-05
CN101252952A (zh) 2008-08-27
IL189620A0 (en) 2008-06-05
KR20080038412A (ko) 2008-05-06
BRPI0615339A2 (pt) 2011-05-17
CA2619445A1 (en) 2007-03-08
US20100197788A9 (en) 2010-08-05
EP1938837A1 (en) 2008-07-02
AU2006285963A1 (en) 2007-03-08
RU2008112176A (ru) 2009-10-10
TW200744635A (en) 2007-12-16
EP1938837A4 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
NO20081550L (no) Preventivt eller terapeutisk middel for sykdom forarsaket av minskning i lakrimalvaeske
DK2170857T3 (da) 3',4',5-trimethoxyflavonderivater som stimulerende middel ved slimafsondring, tilsvarende fremgangsmåde og farmaceutisk præparat, der indeholder disse
Stevens et al. Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial
WO2008137863A3 (en) Methods and devices for measuring tear film and diagnosing tear disorders
JP5616620B2 (ja) 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BRPI0710085B8 (pt) composições oftálmicas e seus kits
NO20076398L (no) Preventivt eller terapeutisk middel for keratokonjunktive forstyrrelser
TWI670057B (zh) 治療乾眼用滴眼劑
BRPI0409622A (pt) derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer
CN103068364B (zh) 不含防腐剂的比马前列素和噻吗洛尔溶液
WO2008059501A3 (en) Use of lipid conjugates in the treatment of diseases or disorders of the eye
BR112013005438A2 (pt) "agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo."
ES2495965T3 (es) Uso de derivados 2,5-dihidroxibencénicos para el tratamiento de enfermedades oculares
EP1915998A8 (en) Prophylactic or therapeutic agent for corneal/conjunctival disease
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
DE602006008186D1 (de) Neues imprägnierverfahren einer textiloberfläche
CY1111384T1 (el) Διαμορφωση των επιπεδων εκφρασης toy trpv
JP5725786B2 (ja) 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
WO2008055205A3 (en) Pai-1 binding modulators for the treatment of ocular disorders
US20080039423A1 (en) Ophthalmic Composition Containing Xanthan Gum and Amino Acid
MA40847A (fr) Association comprenant de la spiruline et du palmitoyléthanolamide et/ou des sels ou des dérivés pharmaceutiquement acceptables de ceux-ci et leurs formulations, pour une utilisation dans la prévention et/ou le traitement d'états d'hyperactivité des tissus
CN105555268B (zh) 阴离子性软隐形眼镜用眼科用组合物

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application